# Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy

## TL;DR

Dinutuximab beta, when combined with chemotherapy, significantly reduces tumor growth and improves survival in a mouse model of Ewing sarcoma.

## Contribution

The study demonstrates the synergistic efficacy of dinutuximab beta and chemotherapy in treating Ewing sarcoma.

## Key findings

- Dinutuximab beta suppressed tumor growth by 60% and improved survival by 68% in a mouse model.
- Combination therapy with doxorubicin enhanced tumor suppression to 86% and survival extension to 146%.
- Dinutuximab beta recruits immune cells to induce tumor cell death.

## Abstract

Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues primarily affecting children and young adults. Prognosis for patients with metastatic or recurrent disease remains poor despite intensive multimodal therapy, highlighting the need of novel therapeutic approaches. The disialoganglioside GD2 is highly expressed on Ewing sarcoma cells, making this tumor eligible for anti-GD2 immunotherapy with dinutuximab beta. Through in vitro and in vivo approaches, this study demonstrated that dinutuximab beta effectively suppressed tumor growth by 60% (p = 0.0135) and improved survival rate by 68% (p = 0.0006) in a mouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacy compared to monotherapy, with enhanced tumor suppression (86%; p = 0.0009) and an extension of survival rate (146%; p = 0.000025). This study showed that dinutuximab beta, particularly in combination with standard chemotherapy, offers a promising approach to improve outcomes for high-risk Ewing sarcoma patients, providing a more effective alternative to current treatments.

•Dinutuximab beta inhibits tumor growth and prolongs survival in a murine Ewing sarcoma model•Combining dinutuximab beta with standard chemotherapy elicits synergistic anti-tumor effect•Dinutuximab beta acts by recruiting immune effector cells that induce tumor cell death•Dinutuximab beta with chemotherapy may improve outcomes and survival in Ewing sarcoma patients

Dinutuximab beta inhibits tumor growth and prolongs survival in a murine Ewing sarcoma model

Combining dinutuximab beta with standard chemotherapy elicits synergistic anti-tumor effect

Dinutuximab beta acts by recruiting immune effector cells that induce tumor cell death

Dinutuximab beta with chemotherapy may improve outcomes and survival in Ewing sarcoma patients

Health sciences; pharmaceutical science